- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00070733
The Effect of 5-Alpha Reductase on Testosterone in Men
The Role of 5-Alpha Reductase in Mediating Testosterone Actions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Testosterone, the predominant circulating androgen in men, serves as the active hormone in some target tissues; however, testosterone effects in other target organs require its conversion to two active metabolites, estradiol 17-beta and DHT. The role of 5-alpha reductase in mediating testosterone's effects on muscle and sexual function remains unclear. This study will determine whether 5-alpha reduction of testosterone to DHT is necessary for mediating effects on fat-free mass, muscle size, muscle strength, and leg power in men. The study will also evaluate the necessity of 5-alpha reductase for maintenance of androgen effects on sexual function (sexual desire, overall sexual activity, nocturnal penile tumescence [NPT], response to visual erotic stimulus, and penile rigidity) in men.
Participants in this study will be treated with a drug to suppress endogenous testosterone production. Participants will then be randomly assigned to receive either testosterone and placebo or testosterone and the 5-alpha reductase inhibitor dutasteride. Testosterone will be administered weekly; dutasteride and placebo will both be administered daily. Diet and exercise will be standardized across both groups. Participants will be assessed at study entry and Week 20. Assessments will include measurements such as a DEXA scan, MRI scan, and muscle performance and sexual function tests. Participants will also have blood tests for safety monitoring; blood tests will include measures of hematocrit, liver enzymes (AST and ALT), prostate specific antigen (PSA), and cholesterol.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90059
- Recruiting
- Charles R. Drew University
-
Contact:
- Shalender Bhasin, MD
- Phone Number: 323-563-9353
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- General good health and capable of undergoing strength testing
- Normal testosterone (300-1100 ng/dL), LH, and FSH levels
Exclusion Criteria
- Currently participating in competitive sports
- Mental state that would preclude complete understanding of the protocol and compliance
- Disorder known to cause or be associated with hypogonadism (e.g., pituitary tumors, hyperprolactinemia, HIV infection, or Klinefelter's Syndrome)
- More than 20% over ideal body weight
- Disabilities that would prevent participation in strength testing (e.g., amputation of limbs, blindness, severe arthritis, angina, or neurologic disorders such as Parkinson's disease, stroke, or myopathy)
- Uncontrolled hypertension, diabetes, congestive heart failure, or chronic obstructive lung disease
- Alcohol or drug dependence in the 6 months prior to study entry
- Disorders that might be exacerbated by androgen treatment (e.g., benign prostatic hyperplasia or prostate cancer, erythrocytosis [hematocrit > 51% at baseline], or sleep apnea assessed by Berlin's questionnaire)
- Serum PSA levels > 4 microg/L
- AST, ALT, or alkaline phosphatase elevation greater than three times the upper limit of normal
- Creatinine greater than 2 mg/dL
- Medications that might affect muscle or bone metabolism (e.g., glucocorticoid, rhGH, androgenic steroids, oral androgen precursors such as androstenedione or DHEA) or androgen metabolism, action, or clearance (e.g., dilantin, phenobarbitol, aldactone, flutamide, finasteride)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Investigators
- Principal Investigator: Shalender Bhasin, MD, Charles R. Drew University
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Sexual Dysfunction, Physiological
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Androgens
- Anabolic Agents
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
Other Study ID Numbers
- R01HD043348-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sex Disorders
-
University of Nebraska LincolnCenters for Disease Control and Prevention; The Set Me Free Project; Des Moines...RecruitingSexual Violence | Sex Trafficking | Child Abuse, Sexual | Sex Crimes | Commercial Sex | Sex OffenseUnited States
-
University of California, San FranciscoPatient-Centered Outcomes Research InstituteCompletedUnsafe Sex | Unprotected SexUnited States
-
National Human Genome Research Institute (NHGRI)CompletedKlinefelter SyndromeUnited States
-
University of Wisconsin, MadisonSolvay PharmaceuticalsWithdrawnKlinefelter SyndromeUnited States
-
University of AarhusAarhus University HospitalCompletedKlinefelter SyndromeDenmark
-
Boston Children's HospitalCompleted
-
Johns Hopkins Bloomberg School of Public HealthCompletedPregnancy | Contraception | Alcohol Use | Drug Use | Unprotected Sex | SexUnited States
-
The University of Hong KongCompletedAdolescent Behavior | Behavior, Sex | Sex, UnsafeHong Kong
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedKlinefelter SyndromeUnited States
-
University of Colorado, DenverNational Institute of Neurological Disorders and Stroke (NINDS); Children's... and other collaboratorsCompletedKlinefelter Syndrome | XXY SyndromeUnited States
Clinical Trials on testosterone enanthate
-
Leonard S. Marks, M.D.Watson Pharmaceuticals; Solvay PharmaceuticalsCompletedMen With Low Testosterone LevelsUnited States
-
Sports Medicine Research and Testing LaboratoryEnrolling by invitation
-
The University of Texas Medical Branch, GalvestonNational Cancer Institute (NCI)CompletedCachexia | Squamous Cell CarcinomaUnited States
-
University of British ColumbiaVancouver Coastal Health Research InstituteCompleted
-
University of Southern CaliforniaBoston University; University of OregonCompletedOsteoarthritis | Trauma | Muscle Atrophy | ACL ReconstructionUnited States
-
The University of Texas Medical Branch, GalvestonWithdrawn
-
The University of Texas Medical Branch, GalvestonTerminated
-
Pennington Biomedical Research CenterUnited States Department of Defense; Defence Research and Development Canada; United States Army Research Institute of Environmental Medicine and other collaboratorsCompletedExercise | Caloric RestrictionUnited States
-
The University of Texas Medical Branch, GalvestonCompleted
-
Antares Pharma Inc.Completed